Anavex Life Sciences (NASDAQ:AVXL) Upgraded at Wall Street Zen
Anavex Life Sciences (NASDAQ:AVXL) was upgraded by Wall Street Zen from "sell" to "hold," resulting in a consensus "Hold" rating and a $22.00 target price. Despite beating quarterly EPS estimates, the company faces a negative FY2026 EPS outlook, with its stock trading below key moving averages. Institutional ownership has increased, with State Street Corp significantly boosting its stake, now holding approximately 31.55% of the company's shares.
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2026 Earnings Call Transcript
Anavex Life Sciences Corp. discussed its Q1 2026 financial results and advancements in its clinical pipeline, particularly for oral blarcamesine in early Alzheimer's disease. The company addressed the EMA's negative opinion on blarcamesine's marketing authorization application, stating it is undergoing reexamination, and detailed plans for an upcoming FDA submission. Anavex also highlighted its participation in the European Access AD initiative, which will include a dedicated clinical trial for blarcamesine.
ANAVEX LIFE SCIENCES CORP. SEC 10-Q Report
Anavex Life Sciences Corp. released its Form 10-Q report for the third quarter, reporting significantly improved financial performance with reduced operating and net losses. The biopharmaceutical company highlighted operational advancements, including ongoing clinical trials for central nervous system diseases like Alzheimer's and Parkinson's, regulatory submissions, and a precision medicine approach. Anavex plans to continue advancing its clinical programs and seek strategic partnerships, leveraging its Orphan Drug and Fast Track designations for ANAVEX®2-73.
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot
Anavex Life Sciences Corp. (AVXL) reported a fiscal first-quarter loss of $5.7 million, or 6 cents per share. The company's shares closed at $4.10, a significant decrease from $8.51 a year ago. This financial update was generated by Automated Insights using Zacks Investment Research data.
Anavex (Nasdaq: AVXL) narrows Q1 loss and boosts cash reserves
Anavex Life Sciences Corp. reported a significantly narrower net loss of $5.7 million in fiscal Q1 2026, down from $12.1 million in the prior year, primarily due to reduced operating expenses. The company also strengthened its cash reserves, ending the quarter with $131.7 million, and continues to focus on advancing its lead candidate, blarcamesine, for Alzheimer's and other CNS disorders. Anavex anticipates a cash runway of over three years at its current utilization rate.
Anavex Life Sciences: Overview of Fiscal First Quarter Earnings
Anavex Life Sciences has reported a net loss of $5.7 million for its fiscal first quarter, translating to a loss of $0.06 per share. The company's shares closed at $4.10, marking a substantial drop from $8.51 recorded in the same period last year. This financial update details the company's performance for the quarter.
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
Anavex Life Sciences announced that it will release its fiscal 2026 first quarter financial results on Monday, February 9, 2026. The company is focused on developing innovative oral medicines to improve the lives of patients with brain health conditions, including Alzheimer's, Parkinson's, and Rett Syndrome. This announcement provides investors and the public with the scheduled date for their upcoming financial report.
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
Anavex Life Sciences announced that it will release its fiscal first-quarter 2026 financial results on Monday, February 9, 2026. The company will also host a conference call and webcast on the same day at 8:30 am ET to discuss the financial results and recent corporate developments, followed by a question-and-answer session. A replay of the conference call will be available on Anavex’s website for up to 30 days.
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
Anavex Life Sciences Corp. announced it will release its fiscal 2026 first-quarter financial results on Monday, February 9, 2026. The company will host a conference call and webcast at 8:30 AM ET to discuss the financial outcomes and recent corporate developments, followed by a Q&A session. Anavex Life Sciences is a biopharmaceutical company focused on developing treatments for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders.
Anavex Life Sciences (NASDAQ:AVXL) Stock Passes Above 50-Day Moving Average - Here's Why
Anavex Life Sciences (NASDAQ:AVXL) stock recently traded above its 50-day moving average, reaching $5.26. Analysts currently rate the stock as a "Hold" with a consensus price target of $22.00, despite mixed recommendations. The clinical-stage biotech company, developing treatments for Alzheimer's and Parkinson's disease, recently surpassed quarterly EPS estimates.
H.C. Wainwright reiterates Buy rating on Anavex Life Sciences stock
H.C. Wainwright has reiterated a Buy rating on Anavex Life Sciences (NASDAQ:AVXL) with a $20.00 price target, following the company's recent interactions with the FDA regarding its Alzheimer’s disease drug candidate, blarcamesine. This price target suggests a 299% upside from the current share price. The company maintains strong financial stability and is progressing in discussions with the FDA for a potential New Drug Application for blarcamesine in Alzheimer’s treatment.
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
Anavex Life Sciences announced that the FDA invited the company to present its Alzheimer's disease clinical trial results, indicating agency interest in their progress. During a Type C meeting, the FDA showed a collaborative approach, and Anavex presented information on blarcamesine, an orally administered therapy with no significant safety concerns. The company will submit existing data from its Phase IIb/III ANAVEX2-73-AD-004 program to advance a potential New Drug Application.
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
Anavex Life Sciences announced its participation in ACCESS-AD, a European initiative funded by the European Commission, aimed at accelerating the adoption of innovative diagnostic and therapeutic approaches for Alzheimer's disease. As part of this consortium, blarcamesine, Anavex's investigational small-molecule therapy, will be clinically evaluated within a precision medicine framework. This collaboration seeks to integrate advanced biomarker data and digital tools to develop accessible and scalable personalized care for Alzheimer's patients across Europe.
Anavex Life Sciences Corp. Joins ACCESS-AD Initiative to Support Innovative Alzheimer's Disease Treatments in Europe
Anavex Life Sciences Corp. has joined ACCESS-AD, a European initiative funded by the European Commission, aimed at enhancing the diagnosis and treatment of Alzheimer's disease. The five-year program will evaluate Anavex's investigational therapy, blarcamesine, as a precision medicine approach within a framework integrating advanced neuroimaging, biomarkers, and digital tools. This collaboration positions Anavex as a key partner in addressing the urgent need for scalable and accessible Alzheimer's treatments in Europe.
Anavex Life Sciences Corp. Joins ACCESS-AD Initiative to Support Innovative Alzheimer's Disease Treatments in Europe
Anavex Life Sciences Corp. has joined ACCESS-AD, a European initiative funded by the European Commission, to improve the diagnosis and treatment of Alzheimer's disease. As a key industry partner, Anavex will evaluate its investigational therapy, blarcamesine, within this five-year program. The initiative aims to integrate advanced diagnostics and personalized treatment approaches to address the growing prevalence of Alzheimer's in Europe.
Anavex Life Sciences Corp. Joins ACCESS-AD Initiative to Support Innovative Alzheimer's Disease Treatments in Europe
Anavex Life Sciences Corp. has joined ACCESS-AD, a European initiative funded by the European Commission, to advance innovative diagnostic and therapeutic approaches for Alzheimer's disease. The five-year program will evaluate Anavex's investigational therapy, blarcamesine, as a precision medicine approach within a coordinated clinical framework. This collaboration aims to accelerate access to effective AD care by integrating advanced neuroimaging, biomarkers, and digital tools.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows a significant 35.94% drop in Anavex's stock price on November 14, 2025, after the European Medicines Agency (EMA) issued a negative trend vote on the Marketing Authorisation Application for blarcamesine. Investors are encouraged to contact Pomerantz LLP for more information about potentially joining a class action.
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
Anavex Life Sciences has requested the European Medicines Agency (EMA) to re-examine its opinion on blarcamesine for the treatment of early Alzheimer's disease. The re-examination will be led by new rapporteurs and may include consultation with a Scientific Advisory Group. Anavex emphasized the significant unmet need for new oral treatment options for Alzheimer's and remains committed to working with regulatory authorities.
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
Anavex Life Sciences Corp. has appointed Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology. Dr. Liedtke brings over 25 years of experience in CNS drug development, having previously served as Chair of Neurology at Regeneron and a Tenured Full Professor at Duke University. He will play a crucial role in advancing Anavex's mission to develop innovative treatments for neurodegenerative and neurodevelopmental disorders.
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
Anavex Life Sciences Corp. (Nasdaq: AVXL) has appointed Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology. Dr. Liedtke brings over 25 years of experience in CNS diseases, with a background at Regeneron and Duke University. He will play a key role in advancing Anavex's mission to develop treatments for neurodegenerative and neurodevelopmental disorders like Alzheimer's and Parkinson's.
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm
Edelson Lechtzin LLP has announced an investigation into Anavex Life Sciences Corp. (NASDAQ: AVXL) for potential violations of federal securities laws, stemming from allegations of misleading business information. This investigation follows a significant drop in Anavex's stock price after the European Medicines Agency issued an unfavorable preliminary opinion on its marketing application for blarcamesine. The firm encourages Anavex investors who have suffered substantial losses to contact them for more information.
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
Anavex Life Sciences has appointed Wolfgang Liedtke, MD PhD, as Senior Vice President, Global Head of Neurology. Dr. Liedtke brings over 25 years of experience in CNS disease treatment development, including significant leadership roles at Regeneron and Duke University. His expertise in neurodegeneration, pain research, and translational neuroscience is expected to significantly contribute to Anavex's mission of developing innovative treatments for neurological disorders.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows a significant 35.94% drop in Anavex's stock price on November 14, 2025, after the European Medicines Agency's committee issued a negative trend vote on its Marketing Authorisation Application for blarcamesine. Investors affected by this decline are advised to contact Danielle Peyton at Pomerantz LLP.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anavex Life Sciences Corp. – AVXL
Pomerantz LLP is investigating potential securities fraud claims against Anavex Life Sciences Corp. (AVXL) on behalf of its investors. This investigation follows a significant 35.94% stock price drop on November 14, 2025, after the European Medicines Agency (EMA) issued a negative trend vote on blarcamesine's Marketing Authorisation Application. Investors who suffered losses are encouraged to contact the law firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating potential securities fraud claims against Anavex Life Sciences Corp. (NASDAQ: AVXL) following a significant drop in its stock price. This investigation arises after the European Medicines Agency indicated a negative trend vote on Anavex's Marketing Authorisation Application for blarcamesine, leading to a 35.94% stock price fall on November 14, 2025. Investors are encouraged to contact Pomerantz LLP for more information.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for potential securities fraud following a significant stock price drop. This drop occurred after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative trend vote on blarcamesine's Marketing Authorisation Application. Investors are encouraged to contact Pomerantz LLP for more information regarding joining a potential class action lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating Anavex Life Sciences Corp. (NASDAQ:AVXL) regarding potential securities fraud and unlawful business practices. This investigation follows a significant 35.94% drop in Anavex's stock price on November 14, 2025, after the European Medicines Agency indicated a negative trend vote for its Marketing Authorisation Application for blarcamesine. Investors are encouraged to contact Pomerantz LLP for information about joining the class action.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) on behalf of investors regarding potential securities fraud or unlawful business practices. This investigation follows a significant 35.94% drop in Anavex's stock price on November 14, 2025, after the European Medicines Agency (EMA) issued a negative trend vote on its Marketing Authorisation Application for blarcamesine. Investors are encouraged to contact Pomerantz LLP for information about joining a potential class action.
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for alleged securities law violations after the European Medicines Agency (EMA) issued a negative trend vote on the Marketing Authorisation Application for blarcamesine. This news caused Anavex's stock to fall by over 35.9%. Shareholders who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights.
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Anavex Life Sciences Corp. (AVXL) on behalf of investors for potential securities law violations. This investigation follows a negative trend vote from the European Medicines Agency on Anavex's blarcamesine Marketing Authorisation Application, which led to a significant drop in the company's stock. Shareholders who incurred losses are encouraged to contact the Schall Law Firm for more information.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) on behalf of investors for potential securities fraud or unlawful business practices. This probe follows a significant 35.94% stock price drop on November 14, 2025, after the European Medicines Agency indicated a negative trend vote on blarcamesine's Marketing Authorisation Application. Investors are encouraged to contact Pomerantz LLP for information regarding joining a potential class action.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for potential securities fraud and unlawful business practices. This investigation follows a significant stock price drop on November 14, 2025, after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative trend vote on Anavex's Marketing Authorisation Application for blarcamesine. Investors are encouraged to contact Pomerantz LLP to learn more about joining a potential class-action lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows a significant drop in Anavex's stock price after the European Medicines Agency's Committee for Medicinal Products for Human Use gave a negative trend vote on the Marketing Authorisation Application for blarcamesine. Investors affected by this decline are encouraged to contact Pomerantz LLP for information regarding potential class action involvement.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) on behalf of investors following a significant stock price drop. The investigation stems from a negative trend vote by the European Medicines Agency (EMA) on Anavex's Marketing Authorisation Application for blarcamesine, which caused Anavex's stock to fall 35.94%. Investors are encouraged to contact Pomerantz LLP for information regarding a potential class action.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) on behalf of investors, following a significant drop in its stock price. The investigation concerns potential securities fraud after Anavex disclosed a negative trend vote from the European Medicines Agency regarding its blarcamesine marketing application, causing a 35.94% stock decline on November 14, 2025. Investors are encouraged to contact Pomerantz LLP to learn more about joining a potential class action.
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
Anavex Life Sciences Corp. has appealed to the European Medicines Agency (EMA) for a re-examination of its opinion on blarcamesine, intended for early Alzheimer's disease treatment. The company will collaborate with the EMA through this process, which includes a new evaluation by different rapporteurs and a request for an independent recommendation from a Scientific Advisory Group. Anavex highlights the significant unmet need for innovative oral treatments for Alzheimer's and is committed to working with regulatory bodies to advance new options.
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Anavex Life Sciences Corp. announced it will present one oral late-breaking communication and two poster presentations featuring blarcamesine at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, California, from December 1-4, 2025. The presentations will highlight blarcamesine's effects in early Alzheimer's disease patients, including significant clinical improvements and its convenience for patients and families. Dr. Marwan Noel Sabbagh emphasized blarcamesine's upstream mechanism of action in restoring autophagy, crucial for treating Alzheimer's by activating the brain's recycling process.
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
Anavex Life Sciences has requested the European Medicines Agency (EMA) to re-examine its opinion on blarcamesine for the treatment of early Alzheimer's disease. The company seeks a new evaluation by different rapporteurs and a Scientific Advisory Group to provide an independent recommendation, emphasizing the urgent need for innovative oral treatments targeting Alzheimer's pathology. Anavex expresses commitment to collaborating with regulatory bodies to advance new treatment options for patients.
EU regulators asked to revisit an experimental pill for early Alzheimer’s
Anavex Life Sciences (AVXL) has requested the European Medicines Agency (EMA) to re-examine its opinion on blarcamesine, an experimental drug for early Alzheimer's disease. This re-examination will be conducted by a new rapporteur team, with Anavex also asking for an independent recommendation from a Scientific Advisory Group. The company emphasizes that blarcamesine remains investigational, and its approval is not guaranteed.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) on behalf of investors regarding potential securities fraud or unlawful business practices. This probe follows a significant stock price drop for Anavex after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative trend vote on blarcamesine's Marketing Authorisation Application. Investors are encouraged to contact Pomerantz LLP for more information.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for alleged securities fraud and unlawful business practices. This investigation follows a significant stock price drop on November 14, 2025, after the European Medicines Agency's committee issued a negative trend vote on blarcamesine's Marketing Authorisation Application. Investors who experienced losses are encouraged to contact Pomerantz LLP for potential class action participation.
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) for potential securities law violations after the European Medicines Agency (EMA) issued a negative trend vote on its Marketing Authorisation Application for blarcamesine, causing Anavex shares to drop significantly. The firm is encouraging shareholders who suffered losses to participate in the investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows a significant 35.94% stock price drop on November 14, 2025, after the European Medicines Agency (EMA) issued a negative trend vote on Anavex's Marketing Authorisation Application for blarcamesine. Investors affected by this decline are encouraged to contact Pomerantz LLP for information regarding a potential class action.
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
Anavex Life Sciences reported its fiscal 2025 fourth quarter financial results, highlighting ongoing clinical development for blarcamesine in Alzheimer’s, Parkinson’s, and Rett syndrome, and ANAVEX®3-71 for schizophrenia. The company intends to request a re-examination of the CHMP opinion for blarcamesine's Marketing Authorisation Application. Anavex finished the quarter with $102.6 million in cash and anticipates over a 3-year cash runway.
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Anavex Life Sciences announced that the European Medicines Agency's CHMP issued a negative opinion on their marketing authorization application for blarcamesine to treat early Alzheimer’s disease. The company plans to request a re-examination of this opinion, which would involve a new and independent evaluation by different rapporteurs. Anavex emphasized its commitment to working with regulatory authorities to bring new oral treatment options for Alzheimer's patients.
Anavex (NASDAQ: AVXL) to seek CHMP re-exam after EU negative view on blarcamesine
Anavex Life Sciences announced that the European Medicines Agency’s CHMP issued a negative opinion on blarcamesine for early Alzheimer’s disease. The company plans to request a re-examination, which will involve a new set of reviewers. This decision follows a negative trend-vote in November and has historically led to significant stock movements for AVXL.
Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)
Anavex Life Sciences (AVXL) stock dropped sharply after the European Medicines Agency (EMA) recommended refusing marketing authorization for its Alzheimer's drug, Blarcamesine, citing insufficient effectiveness, limited safety characterization, and quality concerns. The company intends to request a re-examination, but the decision introduces significant regulatory risk and a complicated path forward, impacting investor sentiment and analyst forecasts. Despite current cash reserves, the unexpected setback emphasizes the binary nature of clinical-stage biotech investments and shifts the focus to Anavex's ability to address EMA's critiques and navigate potential U.S. regulatory discussions.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating Anavex Life Sciences Corp. (NASDAQ: AVXL) on behalf of investors for potential securities fraud. This investigation follows a significant stock price drop on November 14, 2025, after Anavex disclosed a negative trend vote from the European Medicines Agency regarding its blarcamesine marketing authorization application. Investors are encouraged to contact Pomerantz LLP to learn more about joining the class action.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating potential securities fraud claims against Anavex Life Sciences Corp. (NASDAQ: AVXL) following a significant stock price drop. This investigation comes after the European Medicines Agency (EMA) issued a negative trend vote on Anavex's Marketing Authorisation Application for blarcamesine, causing Anavex's stock to fall over 35%. Investors are encouraged to contact Pomerantz LLP for information regarding a potential class action.
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Anavex Life Sciences Corp. ($AVXL) for potential violations of securities laws. This investigation follows a significant 35.9% drop in Anavex's stock price after the European Medicines Agency's CHMP issued a negative trend vote on its Marketing Authorisation Application for blarcamesine. Shareholders who suffered losses are encouraged to contact the firm for a fraud investigation.
